Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China

por Gong, Jinhong, Wan, Qian, Shang, Jingjing, Qian, Xiaodan, Su, Dan, Sun, Zhiqiang, Liu, Guangjun
Publicado 2021

Trends of Antibiotic Use and Expenditure After an Intensified Antimicrobial Stewardship Policy at a 2,200-Bed Teaching Hospital in China

por Qian, Xiaodan, Pan, Yuyan, Su, Dan, Gong, Jinhong, Xu, Shan, Lin, Ying, Li, Xin
Publicado 2021